Duke Hematologic Malignancies & Cellular Therapy

📝 Updated data from the KOMET-007 trial, presented by Harry Erba at #EHA2025, show that ziftomenib with intensive induction therapy was well tolerated in patients with newly diagnosed NPM1m or KMT2Ar AML. More news: aml-hub.com #AMLsm #leusm #MedNews #MedEd

Congratulations to @DukeCancer faculty Dr. Yubin Kang for his new @CancerResearch CLIP award studying how targeting SK2 can enhance CAR T cell therapy efficacy in multiple myeloma #mmsm cancerresearch.org/wp-content/upl…

Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses. #MDS | @tomleblancMD @DukeCancer hubs.li/Q03wgGSn0

Take a look at this review of advancements in countermeasures against #radiation injuries from the Centers for Medical Countermeasures against Radiation Consortium (CMCRC), with former @DukeHMCT division chief #NelsonChao as senior author. pubmed.ncbi.nlm.nih.gov/40571995/

This @CIBMTR retrospective study showed that solid organ transplant outcomes following stem cell transplantation varied depending on the organ transplanted. Liver transplants had worse outcomes compared to kidney transplants. Featuring @horwi001 as a co-author.…

The BELLINI trial showed that Vd-ven had worse overall survival than Vd-placebo in patients with relapsed multiple #myeloma, indicating that #venetoclax should be avoided in the general R/R myeloma population. Featuring @Cristin53875581 as an author. thelancet.com/journals/lanha…

Congratulations to our faculty @tomleblancMD for this important work!

Explore the complexities of chronic #GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies in this article from Targeted Oncology: hubs.li/Q03tll7V0 | @DukeHMCT @dukemedicine @DukeHealth

Preclinical and early phase clinical data suggests a role for dual #FLT3 and MDM2 inhibition using #quizartinib and #milademetan in FLT3-ITD mutated #AML, featuring faculty #HarryErba as a co-author. @CCR_AACR #leusm aacrjournals.org/clincancerres/…

This cross-sectional study in @JCOOP_ASCO showed that cancer survivors were more likely to get alcohol screening, with similar rates of alcohol intervention when needed, highlighting opportunities for improvement. Featuring Vice-Chief @AndreaSitlinger. ascopubs.org/doi/10.1200/OP…

A multicenter study from the U.S. #MultipleMyeloma Immunotherapy Consortium demonstrated the safety and efficacy of #teclistamab in real-world patients, featuring @DukeU @ChenyuLinMD and #DanielSchrum @BloodCancerJnl #MMsm nature.com/articles/s4140…

We are hiring for a Quality Program manager position for the @DukeCancer @DukeHealth Adult and Pediatric Transplant, Cellular Therapy, and Gene Therapy program. Apply here: careers.dukehealth.org/us/en/job/2586…

A @DukeCancer retrospective study suggested that #belantamab has efficacy in real world populations despite a high incidence of keratopathy, led by faculty @tomleblancMD and including @Cristin53875581 @DoctorCAC clinical-lymphoma-myeloma-leukemia.com/article/S2152-…

This @CIBMTR registry study published in @Bloodneoplasia showed similar survival and faster neutrophil engraftment with #omidubicel transplantation vs. alternative stem cell sources, led by @DukeCancer faculty @ChenyuLinMD @horwi001. #BMTsm #CordBlood ashpublications.org/bloodneoplasia…

A match-adjusted indirect treatment comparison of elranatamab and teclistamab showed longer progression-free survival, overall survival, and duration of response with #elranatamab, featuring @tomleblancMD as a co-author. dovepress.com/matching-adjus…

Check out the @NIH chronic #GVHD Consensus Conference 2025 update, featuring @DukeHMCT division chief #StefanieSarantopoulos as an author: sciencedirect.com/science/articl…

A retrospective study in the National Palliative Care Registry showed that a low % of patients w/ metastatic cancer received early palliative care, with some diagnoses, co-morbidities, and complications more predictive of use. @tomleblancMD @JPSMjournal jpsmjournal.com/article/S0885-…

Virtual reality technology may be feasibly used for clinical trial education and consent, in a pilot study featuring @DukeCancer #NelsonChao as co-author. mdpi.com/2072-6694/17/7…

An important review of novel targeted therapies approved for #AML over the past 10 years, and promising treatments still on the horizon, featuring @DukeCancer faculty #HarryErba. @AjHematology #leusm onlinelibrary.wiley.com/doi/10.1002/aj…